Subsidies & Funding

We empower medical innovation

Project Management

We manage research & innovation projects

Business Strategy

We support successful commercialisation

News

Successful autonomous late-stage biotech financing without being eaten

August 04 2020

Many biotech firms aim for an exit through acquisition by a larger biotech or a pharmaceutical company. But what are the options to fund growth and scale operations (including financing later-stage clinical trials)? For example, to prosper late-stage biotech firms that wish to stay autonomous? 

In our newest blog post we introduce the options open to biotech companies valuated beyond €100 million that exceeded the phase of business angels and early stage venture capitalists.

                                                             

We observe that promising ideas fail to survive the valley of death repeatedly. Even the best inventions simply fail to create real impact on end-users. To increase the chances of innovative companies to become and stay successful in the future and to relieve the pressure on business leaders, ttopstart’s corporate finance team offers services for drafting and executing adaptable finance strategies through all the life-cycle phases. 

About ttopstart and corporate finance

Together with INNFLOW we have an interdisciplinary team of 40 sector and finance consultants that build financial structures, pursue de-risking, shape finance and growth strategies, and prepare and execute capital raising for tomorrow’s innovators. INNFLOW is the corporate finance boutique of the PNO group and is focused on sustainable financing and advisory in the sectors Life Sciences & Health, Energy & Climate and for tech driven Scale Ups specifically.

 

Share this